Opus Genetics Secures $25 Million Private Placement of Convertible Preferred Stock
IRD has more than doubled off its 52-week low of $0.65.
Summary
Opus Genetics, Inc. announced a private placement of Series B Non-Voting Convertible Preferred Stock, raising approximately $25.0 million to fund its gene therapy clinical programs and for general corporate purposes.
Key Events · Financing and Capital Events · IRD
-
Private Placement Details
Opus Genetics raised approximately $25.0 million through the private placement of 7,374,632 shares of Series B Non-Voting Convertible Preferred Stock at a purchase price of $3.39 per share.
-
Use of Proceeds
The net proceeds are intended to advance the company's gene therapy clinical programs, as well as for working capital and general corporate purposes.
-
Convertible Preferred Stock Terms
The Series B Preferred Stock is non-voting but convertible into common stock at a 1:1 ratio, subject to stockholder approval at the 2026 annual meeting and beneficial ownership limitations (0-19.9%).
-
Enhanced Liquidity
The financing increases the company's preliminary cash balance from $45 million to a pro forma $70 million as of December 31, 2025, significantly extending its financial runway.
Analysis · IRD · Life Sciences
Opus Genetics, Inc. has announced a significant capital raise through a private placement of Series B Non-Voting Convertible Preferred Stock, generating approximately $25.0 million. This financing is crucial for the life sciences company, as the proceeds are earmarked to advance its gene therapy clinical programs, as well as for working capital and general corporate purposes. The Series B Preferred Stock, priced at $3.39 per share, is convertible into common stock at a 1:1 ratio, contingent upon stockholder approval and subject to beneficial ownership limitations. This capital infusion substantially boosts the company's liquidity, increasing its preliminary cash balance from $45 million to a pro forma $70 million as of December 31, 2025. This strategic financing directly supports the pipeline advancements and corporate initiatives that the company highlighted in its January 2026 filings, providing necessary runway for its operations.
At the time of this filing, IRD was trading at $3.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $246.2M. The 52-week trading range was $0.65 to $3.97. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.